What if you invested $1000 in BIO on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 20 years, Bio-Rad Laboratories, Inc. has delivered an average annual return of 11.4%. The stock peaked in 2019 with a massive +62.2% gain, while investors faced a downturn in 2022 (-42.8%). Overall, the stock finished in the green 13 times out of 20 years.
Avg Return
+11.4%
Win Rate
65%
13W - 7L
Best
+62.2%
2019
Worst
-42.8%
2022
Performance Consistency
About Bio-Rad Laboratories, Inc.
Visit Website ↗Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of specialized technological products for the life science research and clinical diagnostics markets. The company provides a broad range of products, including instruments, software, consumables, and reagents, used to advance scientific discovery and improve healthcare.
Key Business Segments
Life Science
Develops, manufactures, and markets a broad range of reagents, apparatus, and equipment for use in biological research and discovery.
Clinical Diagnostics
Develops, manufactures, and markets a broad range of products for clinical diagnostics, including instruments, software, and reagents for disease screening, diagnosis, and monitoring.
Key Innovations
- ✓Pioneered the development of Bio-Gel P gel chromatography for protein separation.
- ✓Introduced the first commercially available T4 thyroid function test.
- ✓Developed Droplet Digital PCR technology, which allows for precise and sensitive quantification of nucleic acids.
Historical Milestones
Bio-Rad Laboratories is founded by David and Alice Schwartz.
The company enters the clinical diagnostics market.
Bio-Rad acquires Pasteur Sanofi Diagnostics, expanding its presence in blood virus testing, microbiology, and autoimmunity.
Bio-Rad acquires droplet digital PCR technology.